SAN DIEGO, Oct. 1, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical
VK5211, Viking's lead program for musculoskeletal disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) designed to selectively stimulate muscle and bone formation with reduced activity in peripheral tissues such as skin and prostate. The Phase 2 clinical trial was a randomized, double-blind, placebo-controlled, parallel group, international study designed to evaluate the efficacy, safety and tolerability of VK5211 in patients recovering from hip fracture surgery. A total of 108 patients were randomized to receive once-daily VK5211 doses of 0.5 mg, 1.0 mg, 2.0 mg, or placebo for 12 weeks.
Key results presented at ASBMR included:
"This study highlights the impressive efficacy and safety of VK5211 in a population where no treatment option currently exists. The impressive changes to weight and lean body mass, which exceeded six pounds in the highest dose group, demonstrate VK5211's potent effect in patients who are often characterized as frail and prone to prolonged disability. It is striking that these increases were coupled with reductions in fat mass, indicating a favorable shift in overall body composition," said Brian Lian, Ph.D., chief executive officer of Viking. "In addition, while the study was not powered to demonstrate statistical significance on exploratory endpoints, we are encouraged by the dose-dependent increases in 6-minute walk distance, which exceeded placebo by more than 20 meters at the study's highest dose, suggesting a potential functional benefit to patients. Finally, we are pleased with the safety and tolerability of VK5211 in this study, with no drug-related serious adverse events observed and no clinically meaningful changes in important markers such as hemoglobin, red blood cell counts and coagulation factors."
About VK5211VK5211 is an orally available, non-steroidal selective androgen receptor modulator (SARM) in Phase 2 development for the treatment of patients recovering from non-elective hip fracture surgery. VK5211 belongs to a family of novel orally available, non-steroidal SARM compounds based on tissue-specific gene expression and other functional, cell-based technologies. Viking believes that VK5211 has the potential to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to a tissue-selective mechanism of action and an oral route of administration.
About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a small molecule thyroid beta agonist. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content. VK2809 was shown to be safe and well-tolerated in the study. The company's second clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator. In a Phase 2 trial in patients recovering from hip fracture, patients who received VK5211 experienced significant improvements in measures of lean body mass compared to patients who received placebo. The company is also developing VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes. Additional programs include novel and selective agonists of the thyroid beta receptor for GSD Ia and X-linked adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia. Viking holds exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
Forward-Looking StatementsThis press release contains forward-looking statements regarding Viking Therapeutics, including statements about Viking's expectations regarding its development activities, timelines and milestones, as well as the company's goals and plans regarding VK5211 and VK5211's prospects. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK5211 and VK2809; risks that prior clinical and pre-clinical results may not be replicated; and risks regarding regulatory requirements, among others. These forward-looking statements speak only as of the date hereof. Viking disclaims any obligation to update these forward-looking statements.
View original content:http://www.prnewswire.com/news-releases/viking-therapeutics-presents-results-from-phase-2-study-of-vk5211-in-patients-recovering-from-hip-fracture-in-plenary-oral-presentation-at-asbmr-2018-annual-meeting-300721596.html
SOURCE Viking Therapeutics, Inc.
Subscribe to our Free Newsletters!
Bad eating habits will affect your health as well as your skin and make you look older than your ...
A lump in the armpit can be due to a benign infection, allergy or fatty tissue growth. It is ...
Fennel seeds are a must-have in almost every Indian kitchen due to its health quotient. Here are a ...View All